Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21576151 | 0.73 | NPC1 (0.40) | NPC1RAB9ASMN1; SMN2LMNAIDO1 | |
| SCHEMBL19230495 | 0.73 | NPC1 (0.40) | NPC1RAB9ASMN1; SMN2LMNAIDO1 | |
| SCHEMBL17150851 | 0.73 | NPC1 (0.40) | NPC1RAB9ASMN1; SMN2LMNAIDO1 | |
| SCHEMBL9424953 | 0.73 | PLAU (0.43) | NPC1RAB9ASMN1; SMN2LMNANISCH | |
| SCHEMBL29953162 | 0.72 | NPC1 (0.37) | NPC1RAB9ASMN1; SMN2LMNANISCH | |
| SCHEMBL8634605 | 0.71 | SMN1; SMN2 (0.54) | NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL4157886 | 0.71 | HDAC3 (0.47) | NPC1RAB9ASMN1; SMN2LMNANISCH | |
| SCHEMBL30292048 | 0.71 | SMN1; SMN2 (0.54) | NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL8531662 | 0.70 | HDAC3 (0.43) | NPC1RAB9ASMN1; SMN2LMNAHTT | |
| SCHEMBL21925308 | 0.70 | TSHR (0.52) | NPC1RAB9ASMN1; SMN2LMNASLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111971288-B | Selective inhibitors of protein arginine methyltransferase 5 (PRMT 5) | 普莱鲁德疗法有限公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-111971288-A | Selective inhibitors of protein arginine methyltransferase 5(PRMT5) | 普莱鲁德疗法有限公司 | 2020-11-20 | — | — | CN | disclosed |
| EP-3649166-A1 | PROCESS FOR THE PREPARATION OF FUNCTIONALIZED POLYOXYALKYLENE POLYOLS | Covestro Deutschland AG (DE) | 2020-05-13 | — | — | EP | disclosed |
| US-20190315733-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. | 2019-10-17 | — | — | US | disclosed |
| WO-2003035636-A2 | PROCESS FOR THE PREPARATION OF 3 - ISOCHROMANONE | SYNGENTA LIMITED (GB) | 2003-05-01 | — | — | WO | disclosed |
| CN-1102590-C | Process for preparing 3-isochromanone | ZENECA LTD (GB) | 2003-03-05 | — | — | CN | disclosed |
| EP-0906304-B1 | Process for preparing 3-isochromanone | SYNGENTA LTD (GB) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000037454-A1 | METHOD FOR PRODUCING 3-ISOCHROMANONE | BAYER AKTIENGESELLSCHAFT (DE) | 2000-06-29 | — | — | WO | disclosed |
| US-6008381-A | REACTING ORTHO-TOLYLACETIC ACID WITH SULFURYL CHLORIDE IN PRESENCE OF FREE RADICAL INITIATOR AND TREATING THE FORMED 2-CHLOROMETHYLPHENYLACETIC ACID WITH A BASE | ZENECA LIMITED (GB) | 1999-12-28 | — | — | US | disclosed |
| CN-1222150-A | Process for preparing 3-isochromanone | ZENECA LTD (GB) | 1999-07-07 | — | — | CN | disclosed |
| EP-0480708-B1 | Hydroxyalkylquinoline ether acids as leukotriene antagonists | MERCK FROSST CANADA INC (CA) | 1995-10-11 | — | — | EP | disclosed |
| EP-0399818-B1 | Diarylstyrylquinoline diacids | MERCK FROSST CANADA INC (CA) | 1995-08-16 | — | — | EP | disclosed |
| US-5204358-A | Antiallergens; antiinflammatory agents; treatment of asthma, rhinitis, bronchitis and skin diseases | MERCK FROSST CANADA, INC. (CA) | 1993-04-20 | — | — | US | disclosed |
| US-5104882-A | Leukotriene antagonists | MERCK FROSST CANADA, INC. (CA) | 1992-04-14 | — | — | US | disclosed |
| US-5095109-A | Antitumor | UNIVERSITY OF VERMONT (US) | 1992-03-10 | — | — | US | disclosed |
| EP-0470176-A1 | SUBSTITUTED 3-AMINO CHROMANS. | UPJOHN CO (US) | 1992-02-12 | — | — | EP | disclosed |
| WO-1990015061-A1 | NOVEL ALKALOIDS | THE UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 1990-12-13 | — | — | WO | disclosed |
| US-4935509-A | ANTITUMOR AGENTS | UNIVERSITY OF VERMONT (US) | 1990-06-19 | — | — | US | disclosed |
| EP-0318093-A2 | Diarylquinoline diacids and their use as medicaments | MERCK FROSST CANADA INC. (CA) | 1989-05-31 | — | — | EP | disclosed |
| US-4032656-A | ANTIPROSTAGLANDIN ACTIVITY, ANTIDIARRHEA AGENTS | SMITHKLINE CORPORATION (US) | 1977-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315733-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | NPC1 3090/4885RAB9A 1977/4885SMN1; SMN2 4375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.